ZQ4-96680-53990
5 vaccinations
3 coded responses
39 check-ins
3 free-text entries
1 call case
- Sex
- Female
- Age at first dose
- 66+
- ZIP prefix
- 972 / OR
- Registered
- 2021-03-15
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-03-15
Registered in v-safe
-
2021-03-15
Dose 1 — Pfizer-BioNTech
- 2021-03-15
- 2021-03-17
- 2021-03-18
- 2021-03-19
- 2021-03-20
- 2021-03-21
- 2021-03-23
- 2021-03-29
- 2021-04-05
-
2021-04-12
Dose 2 — Pfizer-BioNTech
- 2021-04-12
- 2021-04-13
- 2021-04-14
- 2021-04-15
- 2021-04-16
- 2021-04-17
- 2021-04-19
- 2021-04-19
- 2021-04-26
- 2021-05-03
- 2021-05-10
- 2021-05-17
- 2021-05-24
- 2021-07-12
-
2021-10-11
Survey response — 6 months, dose 2MedDRA: Ageusia, Anosmia, Brain fog, Breakthrough COVID-19, Decreased appetite, Fatigue, Headache, Pain, Pyrexia, Respiratory tract congestion, SARS-CoV-2 test positive — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationFree text: I contracted Covid-19, breakthrough case, symptoms started 8/19/21. Tested positive 8/22/21. Symptoms included fever, severe congestion & headache, body aches, fatigue, lack of appetite, loss of taste and smell. Recovered, but some brain fog issues.MedDRA releases: 2024-11 · check-in free text available
-
2021-10-11
Report sent to call center — 6 months, dose 2Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prTelehealth, virtual health, or email health consultation · 1 call case(s)
- 2021-10-15
-
2021-10-26
Dose 3 — Pfizer-BioNTech
- 2022-04-12
-
2022-04-15
Dose 4 — Pfizer-BioNTech
-
2022-04-21
Survey response — days 1–6 daily, dose 4MedDRA: COVID-19, Disturbance in attention, Memory impairment — Feeling: Good · Fatigue or tirednessFree text: I contracted Covid 19 in August 2021 before my 3rd vaccine (before the first booster) . Since that time I have had intermittent issues with concentration and memory.MedDRA releases: 2024-11 · check-in free text available
-
2022-04-22
Survey response — day 7, dose 4MedDRA: Disturbance in attention, Memory impairment — Feeling: Good · Fatigue or tirednessFree text: Some intermittent difficulty with focus and memoryMedDRA releases: 2024-11 · check-in free text available
- 2022-04-29
- 2022-05-06
- 2022-05-13
- 2022-05-20
- 2022-05-27
- 2022-07-15
-
2022-09-30
Dose 5 — Pfizer-BioNTech
-
2022-10-04
Health check-in — days 1–6 daily, dose 5Feeling: Good · Muscle or body aches, Fatigue or tirednessAdult check-in
- 2022-10-05
- 2022-10-06
- 2022-10-07
- 2022-10-14
- 2022-12-30
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-03-15 | Pfizer-BioNTech | |
| 2 | 2021-04-12 | Pfizer-BioNTech | |
| 3 | 2021-10-26 | Pfizer-BioNTech | No |
| 4 | 2022-04-15 | Pfizer-BioNTech | No |
| 5 | 2022-09-30 | Pfizer-BioNTech | No |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2021-10-11 | Unsuccessful |
Free text
Release 10 — 6 months, dose 2
Symptoms: I contracted Covid-19, breakthrough case, symptoms started 8/19/21. Tested positive 8/22/21. Symptoms included fever, severe congestion & headache, body aches, fatigue, lack of appetite, loss of taste and smell. Recovered, but some brain fog issues. cut off by CDC
Release 11 — days 1–6 daily, dose 4
Systemic reaction (other): I contracted Covid 19 in August 2021 before my 3rd vaccine (before the first booster) . Since that time I have had intermittent issues with concentration and memory.
Release 11 — day 7, dose 4
Systemic reaction (other): Some intermittent difficulty with focus and memory
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Ageusia | · | · | ✓ |
| SD | Anosmia | · | · | ✓ |
| SD | Brain fog | · | · | ✓ |
| SD | Breakthrough COVID-19 | · | · | ✓ |
| SD | Decreased appetite | · | · | ✓ |
| SD | Fatigue | · | · | ✓ |
| SD | Headache | · | · | ✓ |
| SD | Pain | · | · | ✓ |
| SD | Pyrexia | · | · | ✓ |
| SD | Respiratory tract congestion | · | · | ✓ |
| SD | SARS-CoV-2 test positive | · | · | ✓ |
| SRO | COVID-19 | · | · | ✓ |
| SRO | Disturbance in attention | · | · | ✓ |
| SRO | Memory impairment | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release